109 related articles for article (PubMed ID: 35306114)
21. Association of variations in the
Liu JS; Liu JY; Xiao Q; Li XP; Chen J; Liu ZQ
Front Pharmacol; 2023; 14():1119837. PubMed ID: 36969849
[No Abstract] [Full Text] [Related]
22. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
23. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
[TBL] [Abstract][Full Text] [Related]
24. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
[TBL] [Abstract][Full Text] [Related]
25. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
[TBL] [Abstract][Full Text] [Related]
26. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
[TBL] [Abstract][Full Text] [Related]
27. Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.
Wu F; Hu N; Li Y; Bian B; Xu G; Zheng Y
Cell Oncol (Dordr); 2012 Jun; 35(3):175-80. PubMed ID: 22476961
[TBL] [Abstract][Full Text] [Related]
28. Association of polymorphisms in translesion synthesis genes with prognosis of advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Zhang X; Chen Q; Chen J; He C; Mao J; Dai Y; Yang X; Hu W; Zhu C; Chen B
J Surg Oncol; 2016 Jan; 113(1):17-23. PubMed ID: 26611653
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
Mlak R; Krawczyk P; Ciesielka M; Homa I; Powrózek T; Prendecka M; Kozioł P; Milanowski J; Małecka-Massalska T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):621-9. PubMed ID: 26220844
[TBL] [Abstract][Full Text] [Related]
30. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
Liu HF; Liu JS; Deng JH; Wu RR
Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
[TBL] [Abstract][Full Text] [Related]
31. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
[TBL] [Abstract][Full Text] [Related]
32. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
[TBL] [Abstract][Full Text] [Related]
33. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
[TBL] [Abstract][Full Text] [Related]
34. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
35. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
Wu X; Ye Y; Rosell R; Amos CI; Stewart DJ; Hildebrandt MA; Roth JA; Minna JD; Gu J; Lin J; Buch SC; Nukui T; Ramirez Serrano JL; Taron M; Cassidy A; Lu C; Chang JY; Lippman SM; Hong WK; Spitz MR; Romkes M; Yang P
J Natl Cancer Inst; 2011 May; 103(10):817-25. PubMed ID: 21483023
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
Chen J; Wang Z; Zou T; Cui J; Yin J; Zheng W; Jiang W; Zhou H; Liu Z
Oncotarget; 2016 Aug; 7(34):55741-55756. PubMed ID: 27248474
[TBL] [Abstract][Full Text] [Related]
39. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
[TBL] [Abstract][Full Text] [Related]
40. Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
Wang Y; Xia XB; Tang HZ; Cai JR; Shi XK; Ji HX; Yan XN; Xu T
Mutagenesis; 2021 Aug; 36(4):281-293. PubMed ID: 34132814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]